ClearCount announces closing of $5 million Series B financing round

NewsGuard 100/100 Score

ClearCount Medical Solutions, an innovator of patient safety solutions for the operating room, announced today the close of its $5M Series B financing round. The company will use the funds to drive market penetration and research and development of its RFID-based solutions for hospital patient safety applications. ClearCount has developed the first FDA-cleared sponge counting and detection solution. The round was supported by both new and existing shareholders with participation by its leading shareholder, Draper Triangle Ventures, Midwestern-based Network Partner of Draper Fisher Jurvetson (DFJ).

“ClearCount's patented RFID technology and offerings are more relevant than ever”

"Thanks to the strong backing of our investors, this past year ClearCount completed a valuable distribution deal, signed major new customers and introduced an important new product that is making surgical procedures safer every day," said David Palmer, CEO of ClearCount Medical Solutions.

"ClearCount's patented RFID technology and offerings are more relevant than ever," said Mike Stubler, Managing Director of Draper Triangle. "As improving the quality of healthcare continues to be a national focus, solutions that can also impact the efficiency and value a hospital offers its patients are sure to be adopted. ClearCount has shown this is true with its track record of customer and partnership wins."

Retained sponges are the most frequent and dangerous of retained surgical items (RSIs), a "Never Event" resulting in non-payment to hospitals and significant risk to patients. A large multicenter trial recently demonstrated that as little as a 30 minute surgical delay can nearly double the risk of infectious complications - every minute counts. By eliminating preventable hospital costs and delays associated with RSIs, including additional surgery and infection costs, litigation, unnecessary X-rays and anesthesia, ClearCount's products can provide hospitals an improved reputation at a rapid rate of return on investment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising antibiotic resistance prompts shift to ecological research strategies in infection control